Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H29FO4 |
Molecular Weight | 376.4617 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=VWVSBHGCDBMOOT-IIEHVVJPSA-N
InChI=1S/C22H29FO4/c1-12-8-16-15-5-4-13-9-14(25)6-7-21(13,3)22(15,23)18(27)10-20(16,2)19(12)17(26)11-24/h6-7,9,12,15-16,18-19,24,27H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,18+,19-,20+,21+,22+/m1/s1
Molecular Formula | C22H29FO4 |
Molecular Weight | 376.4617 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003899 |
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204141s000lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003899 |
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204141s000lbl.pdf
Desoximetasone (Topicort®) is a topical anti-inflammatory glucocorticoid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and for the treatment of plaque psoriasis in patients 18 years of age or older. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. They play a role in cellular signaling, immune function, inflammation and protein regulation; however, the precise mechanism of action in psoriasis is unknown. The mechanism of anti-inflammatory activity of the topical corticosteroids is also unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Originator
Sources: https://www.google.com/patents/US3232839
Curator's Comment: Kieslich, K., Kerb, U. and Raspe, G.; US. Patent 3,232,839; February 1,1966; assigned to Schering AG, Germany.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 |
5.5 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TOPICORT Approved UseTopicort® (desoximetasone cream USP) 0.05%, Topicort® (desoximetasone cream USP) 0.25%, and Topicort® (desoximetasone gel USP) 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Launch Date1977 |
|||
Primary | TOPICORT Approved UseTopicort® Topical Spray is a corticosteroid indicated for the treatment of
plaque psoriasis in patients 18 years of age or older. Launch Date2013 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16272 pg × h/mL |
0.25 % 2 times / day steady-state, topical dose: 0.25 % route of administration: Topical experiment type: STEADY-STATE co-administered: |
DESOXIMETASONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Compatibility of desoximetasone and tacrolimus. | 2003 Dec |
|
Quantitative determination of dexamethasone in bovine milk by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. | 2004 Jun 5 |
|
[Psoriasis and mud bath therapy: clinical-experimental study]. | 2005 Jul-Aug |
|
Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. | 2006 Nov |
|
Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing? | 2006 Oct |
|
Cross-reactions to desoximetasone and mometasone furoate in a patient with multiple topical corticosteroid allergies. | 2006 Sep |
|
Iatrogenic hyperadrenocorticism and steatohepatitis caused by unapproved medicine. | 2008 |
|
Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay. | 2008 |
|
Comparison of tissue viability imaging and colorimetry: skin blanching. | 2009 Feb |
|
Emotional lability secondary to the application of a very potent topical corticosteroid. | 2009 Jul-Sep |
|
Compatibility of tacrolimus ointment with corticosteroid ointments of varying potencies. | 2009 May-Jun |
|
Management of alopecia areata. | 2010 Jul 23 |
|
Update on the management of chronic eczema: new approaches and emerging treatment options. | 2010 Jul 28 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Sample Use Guides
Apply a thin film of desoximetasone (Topicort®) to the affected skin areas twice daily. Rub in gently.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11152650
Dexamethasone (DEX) (10^-6 M) downregulated human glucocorticoid receptor alpha (hGRalpha) mRNA at 6 and 24 h (55 +/- 8 and 58 +/- 5% of control, respectively; P < 0.01), whereas it decreased human glucocorticoid receptor beta (hGRbeta) mRNA only at 6 h (55 +/- 7% of control; P < 0.01). Downregulation of hGRalpha and hGRbeta mRNAs occurred even in the presence of cycloheximide. Actinomycin-D studies revealed that DEX enhanced the stabilization of hGRalpha and hGRbeta messages.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:08:11 GMT 2023
by
admin
on
Fri Dec 15 15:08:11 GMT 2023
|
Record UNII |
4E07GXB7AU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD07XC02
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
||
|
NDF-RT |
N0000175450
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
||
|
WHO-VATC |
QD07AC03
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
||
|
WHO-ATC |
D07XC02
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
||
|
WHO-ATC |
D07AC03
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7067
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
SUB07006MIG
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
206-845-3
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
4E07GXB7AU
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
DESOXIMETASONE
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
DTXSID3045647
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
382-67-2
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
C47477
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
759189
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
5311067
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
D003899
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
4E07GXB7AU
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
691037
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
100000083193
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
2467
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL1766
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
819
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
1173508
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | |||
|
DB00547
Created by
admin on Fri Dec 15 15:08:11 GMT 2023 , Edited by admin on Fri Dec 15 15:08:11 GMT 2023
|
PRIMARY | |||
|
m4201
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
3255
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
Desoximetasone
Created by
admin on Fri Dec 15 15:08:12 GMT 2023 , Edited by admin on Fri Dec 15 15:08:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |